Specifically, we observed that 75% of ALS patients had higher levels of leukocyte derived MVs (LMVs, % CD45+/Annexin V+ MVs) as percentage of all MVs subsets than the mean of the non-neurological control individuals and AD patients considered in this study as neurological controls (Figure 1C, ANOVA followed by Bonferroni’s test, p < 0.0001; p < 0.001, respectively). The gene discussed is PTPRC; the disease is Alzheimer disease.